Kenvue (KVUE) Expected to Announce Quarterly Earnings on Thursday

Kenvue (NYSE:KVUE) is projected to announce its earnings results before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings of $0.26 per share and revenue of $3.79 billion for the quarter. Kenvue has set its FY 2024 guidance at 1.100-1.200 EPS and its FY24 guidance at $1.10-1.20 EPS.Persons that wish to register for the company’s earnings conference call can do so using this link.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. The business had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. Kenvue’s quarterly revenue was down .4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.31 EPS. On average, analysts expect Kenvue to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Kenvue Stock Performance

Shares of KVUE stock opened at $20.81 on Wednesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue has a 52 week low of $17.67 and a 52 week high of $24.46. The company’s 50 day moving average price is $21.77 and its two-hundred day moving average price is $21.96. The company has a market capitalization of $39.89 billion, a P/E ratio of 37.83, a price-to-earnings-growth ratio of 2.05 and a beta of 1.45.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.94%. Kenvue’s payout ratio is 149.09%.

Wall Street Analysts Forecast Growth

KVUE has been the subject of a number of research reports. Barclays lowered their target price on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday, January 17th. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $21.00 to $26.00 in a report on Monday, January 6th. Bank of America boosted their target price on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. UBS Group decreased their price target on shares of Kenvue from $24.00 to $23.00 and set a “neutral” rating for the company in a research note on Thursday, January 16th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and cut their price objective for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $23.08.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.